GlobeNewswire by notified

Saniona progresses its Kv7 epilepsy program into Lead Optimization

Share

PRESS RELEASE

August 16, 2022

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7 epilepsy program into the Lead Optimization Phase, which is the last drug discovery phase before potential selection of a clinical candidate.

Thomas Feldthus, CEO: “We believe that we have cracked the main challenges for making the next generation drug candidates of this class and see significant potential for delivering new breakthrough epilepsy treatments. The financial upside could be substantial based on very significant pharma deals recently executed in the Kv7 field”.

Epilepsy, characterized by recurrent seizures, currently affects millions of people worldwide. There is a significant medical need as approximately 30% of patients are insensitive to treatment by conventional epilepsy medicines. Furthermore, anti-seizure therepy may cause disabling side effects and often require careful dose adjustment to minimize these.

Kv7 ion channels are voltage-activated potassium channels that play a critical role by dampening of repetitive firing of neurons, which potentially can lead to seizure activity. The special importance of the Kv7.2/Kv7.3 heteromeric channel within epilepsy is clearly illustrated by the increasing numbers of mutations in Kv7.2 and Kv7.3 that are found to be associated with severe inherited forms of epilepsy. Thus, small molecule drugs that facilitate the opening of Kv7.2/Kv7.3 ion channels have potential to treat epilepsy as well as other neuronal hyperexcitability disorders.

There is proof of concept for the use of Kv7 modulators for treatment of epilepsy as a relatively recently approved non- selective Kv7 anti-seizure drug, ezogabine (retigabine), has demonstrated strong anti-epileptic activity. Unfortunately, this drug had to be withdrawn from the market due to serious adverse effects including skin discoloration, retinal changes, and increased risk of urinary retention, a potentially life-threatening condition. The skin discoloration and retinal changes are caused by ezogabine’s chemical instability and not by the compound’s mode-of-action, whereas the increased risk of urinary retention is believed to be due to the non-selective profile of ezogabine leading to unintentional activation of Kv7 subtypes expressed in the bladder.

Several companies and academic groups have over the past decade worked on developing a next generation drug candidate avoiding the limitations and tolerability issues with ezogabine. Saniona scientists have been active in the Kv7 drug discovery field for more than a decade and have worked in previous Kv7 Pharma partnership programs. Saniona has now managed to progress into lead optimization stage with a new chemical series that circumvent limitations with first generation drug candidates. The main features of these new Kv7 activators are improved chemical stability as well as differentiation in selectivity and mechanism-of-action, which can eliminate relaxation of bladder tissue. The objective of the lead optimization program is thus to develop a second generation Kv7 medicine without the side effects that led to the withdrawal of exogabine from the market.

Palle Christophersen, EVP Research: “Kv7 activation has been clinically validated as an effective anti-epileptic concept, but a new medicine is highly warranted. I strongly believe that an optimized candidate from our new Kv7 program will address unmet medical needs in difficult-to-treat patients, such as treatment-resistant partiel onset epilepsies and pediatric epilepsies caused by Kv7 mutations. By preserving or even improving anti-seizure activity with a chemically stable compound and avoiding unintended bladder relaxation, we are in a strong position to help these patients.”

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

This information was submitted for publication, through the agency of the contact person set out above, at 08.00 CEST onAugust 16, 2022.

About Saniona
Saniona is a clinical-stage biopharmaceutical company with a mission to leverage its ion channel targeting expertise to discover, develop and deliver innovative rare disease treatments. The company’s most advanced product candidate, Tesomet™, has been progressed into mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly owned ion channel modulators, SAN711, SAN903. SAN711 has successfully completed a Phase 1 clinical trial and is positioned for the treatment of neuropathic pain conditions; SAN903 is in preclinical development for rare inflammatory, fibrotic, and hematological disorders. Saniona is based in the Copenhagen area, Denmark, and is listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Aduro Announces Readiness of Scaled-up Continuous Flow Plastic Reactor for Customer Trials6.10.2022 13:00:00 CEST | Press release

SARNIA, Ontario, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into new-era resources and higher-value fuels, announces it is entering final stages of completion of its pilot-scale HydrochemolyticTM continuous flow plastic (“R2 Plastic”) reactor. The R2 Plastic unit is in the final assembly phase, plans for testing, commissioning, and certification are finalised and expected to be complete by mid November 2022. The R2 Plastic unit is the Company’s customer engagement unit and is designed to handle various plastic feedstocks such as polyethylene, polypropylene, and polystyrene as single stream materials, followed by a mixture of these feedstock streams. The R2 Plastic will also be used to evaluate the impact of materials found in multilayer plastics, such as paper, paper b

Nexstim NBS 5+ System Continues to Generate Interest in the US6.10.2022 11:00:00 CEST | Press release

Press release,Helsinki,6October2022 at12PM (EEST) Nexstim NBS 5+ System Continues to Generate Interest in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Drs. Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system. Marangell and Al Jurdi, both previously faculty at Baylor College of Medicine, founded Brain Health Consultants and TMS Center as a private outpatient program offering state of the art treatment for people with depression and related disorders. The NBS 5+ system, released in the United States in 2021, combines the capabilities of Nexstim’s NBS and NBT® systems. It thus enables the delivery of both diagnostic and therapeutic applications; diagnostic use meaning identifying the precise location and amount of stimulation required to active specific nerve cells for use across specialities such as neurosurgery, neuroradiology and psychiatry and therapeutic use referring to the treatment o

Huhtamaki publishes its Q3 2022 Interim Report on October 21, 20226.10.2022 09:00:00 CEST | Press release

HUHTAMÄKI OYJ PRESS RELEASE 6.10.2022 AT 10:00 Huhtamaki publishes its Q3 2022 Interim Report on October 21, 2022 Huhtamäki Oyj will publish its Q3 2022 Interim Report on Friday, October 21, 2022, approximately at 8:30 Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Teleconference Huhtamaki will arrange a combined webcast and teleconference on the same day at 9:30 Finnish time. Huhtamaki´s President and CEO Charles Héaulmé and CFO Thomas Geust will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: https://huhtamaki.videosync.fi/2022-q3-results/ If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland: +358 9 2319 5436 Sweden: +46 (0) 8 5051 0086 UK: +44 (0) 33 0551 0211 US: +1 646 843 4609 Participant Passcode: 0422950# An on-demand replay of the audio

Yara calls for urgent action to reduce Europe’s food dependency on Russia6.10.2022 08:31:11 CEST | Press release

Oslo, October 6, 2022: Yara calls on the European Union and national governments to act urgently and decisively to ensure Europe reduces, and not strengthens, its dependency on Russia for food and fertilizers. A strong European fertilizer industry is crucial not only for ensuring food security in Europe and globally but also for ensuring that Europe can continue to take the lead in the green transition. “It is imperative that the war on Ukraine does not destroy the work towards a net-zero future. It is unthinkable that we will reach the climate targets without a strong, green European industry. Instead of weakening the position of the European fertilizer industry, which is a frontrunner in decarbonization, we need massive, coordinated efforts to reach zero emissions, while at the same time reducing our dependencies on Russia,” says Svein Tore Holsether, President and Chief Executive Officer of Yara. Curtailed production in Europe reduces worldwide availability of fertilizers and has di

Chief Legal Officer Nassib Abou-Khalil to leave Nokia6.10.2022 08:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 6 October 2022 at 9:00 EEST Chief Legal Officer Nassib Abou-Khalil to leave Nokia Espoo, Finland – Nokia’s Chief Legal Officer, Nassib Abou-Khalil, has decided to leave Nokia and step down from its Group Leadership Team. A recruitment process will begin immediately for his successor. Nassib Abou-Khalil joined Nokia in 2014 and was appointed Chief Legal Officer in 2019. Before that role, he held various legal and compliance leadership positions in the company, including working as the general counsel for customer operations and leading the integration of the compliance programs of Alcatel-Lucent and Nokia. “This was a very difficult decision for me. However, after eight years with the company, it’s time for personal renewal and seeking new challenges externally. Whatever I have been able to realize – both as Nokia’s CLO and in our industry-leading inclusion and diversity work – has been possible only because of the support and encouragement I hav